Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Mar
15
Today In Oncology
Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males
p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
Disease Stage at Breast Cancer Diagnosis Impacted by Region Race and Insurance
Can Viral Respiratory Infections Increase Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo